Loading the player.
COVID vaccination key to curbing pandemic but govt doesn t seem to care: Rahul Gandhi
Asserting that the number of daily inoculations in the country has come down, Congress leader Rahul Gandhi on Monday said vaccination is the key to controlling the pandemic but the government does not seem to care. He shared a graph showing the decline in the number of vaccine doses administered during April and May (till 20th) and pointed out that the average number of vaccination per day has fallen below the daily production.
Kia Motors rebrands itself as Kia India
South Korean automaker Kia on Monday said it has officially changed its name in the country to Kia India from Kia Motors earlier. The change of name is part of the company s new brand identity which symbolises it becoming an enterprise that invests in and produces more than just vehicles to offer a long range of sustainable mobility solutions, it said.
Karnataka sets 24-hr deadline for Cipla, Jubilant to supply Remdesivir
Roche India on Monday announced the rollout of its first batch of the antibody cocktail (Casirivimab and Imdevimab) against Coronavirus in India. The cocktail drug will be marketed by Cipla pan-India.
The second batch of the cocktail jabs will be made available by mid-June. Together, they can potentially benefit 200,000 patients as each of the 100,000 packs that will be available in India offers treatment for two patients, the company said in a statement.
The price for each patient dose [a combined dose of 1200 mg (600 mg of Casirivimab and 600 mg of Imdevimab)] will be Rs 59,750. The maximum retail price for the multi-dose pack (each pack can treat two patients) is Rs 119,500, the statement added.
Roche s COVID-19 antibody cocktail launched in India : Bulletin: Business Today businesstoday.in - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from businesstoday.in Daily Mail and Mail on Sunday newspapers.
URL copied
Roche s Covid antibody cocktail launched in India for treatment of mild to moderate cases
Drug majors Roche India and Cipla on Monday announced launch of Roche s Antibody Cocktail in India priced at Rs 59,750 per dose for the treatment of mild to moderate COVID-19 in patients who are at high risk. The first batch of the Antibody Cocktail (Casirivimab and Imdevimab) is now available in India while a second batch will be made available by mid-June. In total they can potentially benefit 2,00,000 patients as each of the 1,00,000 packs that will be available in India offers treatment for two patients, Cipla and Roche said in a joint statement.